biostudies-literatureUnknown6(5)Mooney AHNHMRCCallaghan InnovationNew Zealand Ministry of Business Innovation and EmploymentHealth Research Council of New Zealand<h4>Background & aims</h4>Liver diseases resulting from chronic HBV infection are a significant cause of morbidity and mortality. Vaccines that elicit T-cell responses capable of controlling the virus represent a treatment strategy with potential for long-term effects. Here, we evaluated vaccines that induce the activity of type I natural killer T (NKT) cells to limit viral replication and license stimulation of conventional antiviral T-cells.<h4>Methods</h4>Vaccines were prepared by conjugating peptide epitopes to an NKT-cell agonist to promote co-delivery to antigen-presenting cells, encouraging NKT-cell licensing and stimulation of T cells. Activity of the conjugate vaccines was assessed in transgenic mice expressing the complete HBV genome, administered intravenously to maximise accessJHEP reports : innovation in hepatology101038https://www.ebi.ac.uk/biostudies/studies/S-EPMC11061331biostudies-literaturePreclinical evaluation of therapeutic vaccines for chronic hepatitis B that stimulate antiviral activities of T cells and NKT cells.PMC11061331Heath WRGodfrey DISette AGuidotti LGTang CSidney JChisari FVAnderson RJGiustini LFarrand KJHermans IFGulab SAPainter GFMooney AHBurn OKIannacone MDi Lucia PFumagalli VCompton BJRava MBono EDraper SLYuan WfalsePreclinical evaluation of therapeutic vaccines for chronic hepatitis B that stimulate antiviral activities of T cells and NKT cells.<h4>Background & aims</h4>Liver diseases resulting from chronic HBV infection are a significant cause of morbidity and mortality. Vaccines that elicit T-cell responses capable of controlling the virus represent a treatment strategy with potential for long-term effects. Here, we evaluated vaccines that induce the activity of type I natural killer T (NKT) cells to limit viral replication and license stimulation of conventional antiviral T-cells.<h4>Methods</h4>Vaccines were prepared by conjugating peptide epitopes to an NKT-cell agonist to promote co-delivery to antigen-presenting cells, encouraging NKT-cell licensing and stimulation of T cells. Activity of the conjugate vaccines was assessed in transgenic mice expressing the complete HBV genome, administered intravenously to maximise access2024-01-01T00:00:00Z2024 May2026-06-01T23:38:09.245Z2026-05-23T03:08:08.08ZS-EPMC110613313869495910.1016/j.jhepr.2024.101038